Literature DB >> 33609619

Human umbilical cord mesenchymal stem cells attenuate podocyte injury under high glucose via TLR2 and TLR4 signaling.

Yinghui Wang1, Jiaxi Liu2, Qingqing Zhang1, Weiwei Wang3, Qingzhen Liu4, Shanshan Liu4, Yan Song4, Xueling Wang4, Yaping Zhang4, Shan Li1, Xue Yang1, Shasha Lv5, Gang Liu6.   

Abstract

AIMS: This research aimed to investigate the effects of high glucose (HG) on the innate immunity of podocytes and diabetic nephropathy (DN) mice via Toll like receptor (TLR) signaling, and explore the protective effectsof human umbilical cord mesenchymal stem cells (HUC-MSCs) on this process.
METHODS: HUC-MSCs obtained from human umbilical cord were cocultured with podocytes and transplanted into DN mice. Flow cytometry, CCK-8assay, ELISA, western blot analysis, periodicacid-schiff, masson, immunohistochemistry and immunofluorescence staining was used to detect the inflammation, TLR signaling, physical, biochemical and morphological parameters in podocytes and DN mice.
RESULTS: HG reduced the viability of podocytes, activated TLR2 and TLR4 signaling pathway and increased the expression of inflammatory cytokines such as IL-6, IL-1β, TNF-α, and MCP-1 in podocytes and DN mice. However, HUC-MSCs decreased the inflammation and restrained the TLR signaling pathway caused by HG in vitro and in vivo. Furthermore the rhHGF decreased the expression of TLR2 and TLR4 while the blockade of HGF increased the expression of TLR2 and TLR4 in podocytes.
CONCLUSIONS: HUC-MSCs have benefits to the podocytes under HG and the progression of DN by inhibiting TLR signaling pathway and depressing the inflammation. HUC-MSCs may be a therapeutic strategy for treating patients with DN.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetic nephropathy; Hepatocyte growth factor; Inflammation; Mesenchymal stem cells; Podocytes; Toll-like receptors

Mesh:

Substances:

Year:  2021        PMID: 33609619     DOI: 10.1016/j.diabres.2021.108702

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  4 in total

Review 1.  Extracellular Vesicles Released from Stem Cells as a New Therapeutic Strategy for Primary and Secondary Glomerulonephritis.

Authors:  Marco Quaglia; Guido Merlotti; Laura Fornara; Andrea Colombatto; Vincenzo Cantaluppi
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

2.  Human umbilical cord mesenchymal stem cells contribute to the reconstruction of bladder function after acute spinal cord injury via p38 mitogen-activated protein kinase/nuclear factor-kappa B pathway.

Authors:  Jue Li; Jiliang Huang; Ling Chen; Wei Ren; Wenzhi Cai
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

3.  lncRNA MALAT1 Promotes Diabetic Nephropathy Progression via miR-15b-5p/TLR4 Signaling Axis.

Authors:  Zijun Yang; Dongxu Song; Yulin Wang; Lin Tang
Journal:  J Immunol Res       Date:  2022-07-21       Impact factor: 4.493

4.  Therapeutic potential of conditioned medium obtained from deferoxamine preconditioned umbilical cord mesenchymal stem cells on diabetic nephropathy model.

Authors:  Serbay Ozkan; Basak Isildar; Merve Ercin; Selda Gezginci-Oktayoglu; Dildar Konukoglu; Neşet Neşetoğlu; Mahmut Oncul; Meral Koyuturk
Journal:  Stem Cell Res Ther       Date:  2022-09-02       Impact factor: 8.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.